Pro-Dex (NASDAQ:PDEX) CFO Sells $140,990.00 in Stock

Pro-Dex, Inc. (NASDAQ:PDEX) CFO Alisha Charlton sold 2,300 shares of the firm’s stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $61.30, for a total transaction of $140,990.00. Following the sale, the chief financial officer owned 21,870 shares of the company’s stock, valued at approximately $1,340,631. This represents a 9.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Pro-Dex Stock Down 1.4%

Shares of PDEX traded down $0.86 on Thursday, hitting $59.84. 65,560 shares of the stock traded hands, compared to its average volume of 63,778. Pro-Dex, Inc. has a one year low of $23.47 and a one year high of $77.00. The company has a market capitalization of $191.49 million, a PE ratio of 14.49 and a beta of 0.06. The business has a 50 day simple moving average of $62.39 and a 200 day simple moving average of $57.68. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.45 and a current ratio of 4.10.

Pro-Dex (NASDAQ:PDEX) last released its quarterly earnings data on Thursday, September 3rd. The medical instruments supplier reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.20. The business had revenue of $20.40 million for the quarter, compared to analysts’ expectations of $19.20 million. Pro-Dex had a return on equity of 25.13% and a net margin of 17.62%. As a group, equities analysts forecast that Pro-Dex, Inc. will post 2.78 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PDEX has been the topic of several research analyst reports. Weiss Ratings upgraded shares of Pro-Dex from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, September 4th. Zacks Research raised shares of Pro-Dex to a “hold” rating in a report on Tuesday, May 19th. Finally, Wall Street Zen upgraded shares of Pro-Dex from a “hold” rating to a “buy” rating in a research report on Saturday, June 13th. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $70.00.

Institutional Trading of Pro-Dex

Several large investors have recently modified their holdings of the company. Los Angeles Capital Management LLC purchased a new stake in Pro-Dex during the fourth quarter valued at $37,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Pro-Dex in the second quarter valued at about $50,000. Bank of America Corp DE boosted its position in Pro-Dex by 173.3% in the second quarter. Bank of America Corp DE now owns 1,692 shares of the medical instruments supplier’s stock worth $74,000 after purchasing an additional 1,073 shares during the last quarter. Wells Fargo & Company MN boosted its position in Pro-Dex by 65.4% in the fourth quarter. Wells Fargo & Company MN now owns 2,314 shares of the medical instruments supplier’s stock worth $89,000 after purchasing an additional 915 shares during the last quarter. Finally, California State Teachers Retirement System bought a new stake in shares of Pro-Dex during the 2nd quarter valued at about $99,000. Institutional investors own 15.28% of the company’s stock.

Pro-Dex Company Profile

Pro-Dex, Inc is a designer and manufacturer of precision drive systems and fluid management products serving the dental, medical, industrial and energy markets. The company specializes in high-speed, brushless micromotors and controllers, as well as pneumatic and fluid control devices, providing both standard and custom-engineered solutions for original equipment manufacturers.

Its product portfolio includes high-speed dental handpieces, turbine systems, rotary and reciprocating micro-drives, along with integrated fluid delivery systems.